Silence Therapeutics reported a marked revenue deterioration in QQ2 2024, with revenue of £598 thousand versus substantially higher prior-quarter activity and a YoY decline of approximately 93%. The period was characterized by a substantial operating loss driven by R&D intensity and selling, general and administrative expenses, as the company advances its Phase I programs (notably SLN360 and SLN124) and sustains collaboration-driven activity. Despite the negative profitability metrics, Silence preserves a strong liquidity position and a substantial cash runway, supported by a cash balance of £109.5 million and no material debt, which provides ample flexibility to advance its early-stage pipeline and pursue potential milestone receipts or strategic partnerships.
The quarter underscores Silence’s status as a pre-commercial biotechnology company: low near-term revenue, sizable R&D investment, and a burn that is typical for RNAi platforms in early clinical development. Management commentary (where available) would be instrumental in confirming milestones, readouts, and collaboration negotiations that could meaningfully influence the valuation trajectory. In the absence of a disclosed forward guidance in the QQ2 release, the key expectations for investors hinge on upcoming clinical readouts, potential partner milestones, and any new collaboration dynamics that could unlock non-dilutive financing or accelerate development timelines.